Venture Capital Vi, L.P.Ver... Net Worth

The estimated Net Worth of Venture Capital Vi, L.P.Ver... is at least $11.9 Milione dollars as of 20 October 2020. Venture Ver owns over 200,000 units of Aligos Therapeutics stock worth over $11,901,727 and over the last 4 years Venture sold ALGS stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Venture Ver ALGS stock SEC Form 4 insiders trading

Venture has made over 1 trades of the Aligos Therapeutics stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture bought 200,000 units of ALGS stock worth $3,000,000 on 20 October 2020.

The largest trade Venture's ever made was buying 200,000 units of Aligos Therapeutics stock on 20 October 2020 worth over $3,000,000. On average, Venture trades about 200,000 units every 0 days since 2020. As of 20 October 2020 Venture still owns at least 862,444 units of Aligos Therapeutics stock.

You can see the complete history of Venture Ver stock trades at the bottom of the page.

Insiders trading at Aligos Therapeutics

Over the last 4 years, insiders at Aligos Therapeutics have traded over $0 worth of Aligos Therapeutics stock and bought 9,083,601 units worth $23,279,537 . The most active insiders traders include Holdings A/S Novo, Carole Nuechterlein e Thomas Woiwode. On average, Aligos Therapeutics executives and independent directors trade stock every 220 days with the average trade being worth of $25,070,736. The most recent stock trade was executed by Carole Nuechterlein on 25 October 2023, trading 7,933,601 units of ALGS stock currently worth $6,029,537.

What does Aligos Therapeutics do?

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Complete history of Venture Ver stock trades at Aligos Therapeutics

Aligos Therapeutics executives and stock owners

Aligos Therapeutics executives and other stock owners filed with the SEC include:

• Dr. Lawrence M. Blatt MBA, Ph.D.,
  CEO & Chairman
• Dr. Lawrence M. Blatt,
  CEO & Chairman
• Dr. Leonid Beigelman Ph.D.,
  Pres & Director
• Dr. Leonid Beigelman,
  Pres & Director
• Dr. Julian A. Symons DPHIL,
  Exec. VP & Chief Scientific Officer
• Dr. Julian A. Symons,
  Exec. VP & Chief Scientific Officer
• Yair Keusch,
  External Director
• Maor Israel,
  External Director
• Amir Hayek,
  External Director
• Avraham Burg,
  External Director
• David Wiessman,
  Director
• Ronnie Meninger,
  Director
• Ofer Kotler,
  Director
• Yitzhak Bader,
  Director
• Elli Levinson-Sela,
  General Counsel, Secretary
• Elad Sofer,
  Vice President - Finance
• Zvi Greenfeld,
  Chairman of Alon Management Gas Exploration Ltd., Director
• Eliyahu Misgav,
  Chief Executive Officer
• Haim Elmoznino,
  Chairman of the Board
• Kristina Engeseth,
  Exec. Director and Head of People & Culture
• Dr. Pierre J.M.B. Raboisson Ph.D., Pharm.D.,
  Exec. VP, Head of Small Molecule Medicinal Chemistry & Head of Belgium Site (Leuven)
• Dr. Sushmita M. Chanda DABT, Ph.D.,
  Exec. VP of Translational Safety Sciences
• Lesley Ann Calhoun CPA,
  Exec. VP & CFO
• Dr. Pierre J.M.B. Raboisson Ph.D.,
  Exec. VP, Head of Small Molecule Medicinal Chemistry & Head of Belgium Site (Leuven)
• Dr. David B. Smith Ph.D.,
  Exec. VP & Head of Chemical Operations
• Sushmita M. Chanda DABT, Ph.D.,
  Exec. VP of Translational Safety Sciences
• Dr. Matthew W. McClure M.D.,
  Exec. VP & Chief Medical Officer
• John Fry,
  Exec. VP of Clinical Devel.
• Lucinda Y. Quan J.D.,
  Exec. VP, Chief Bus. Officer & Gen. Counsel
• Lesley Ann Calhoun,
  Exec. VP & CFO
• James Paul Scopa,
  
• Carole Nuechterlein,
  
• Lucinda Y. Quan,
  See Remarks
• Leonid Beigelman,
  President
• Venture Capital Vi, L.P.Ver...,
  
• Capital Viii, Llc Vivo Capi...,
  
• Thomas Woiwode,
  Director
• Biomedical Innovation Maste...,
  10% owner
• Holdings A/S Novo,
  10% owner
• Heather Preston,
  
• Margarita Chavez,
  
• Lesley Ann Calhoun,
  
• Jack Nielsen,
  
• Matthew W. Mc Clure,
  Chief Medical Officer
• Bridget A Martell,
  
• Peter Hirth,
  
• Lawrence Blatt,
  Chief Executive Officer
• Julian A. Symons,
  See Remarks